everolimus + mycophenolate mofetil + corticosteroids

This combination consists of **everolimus**, **mycophenolate mofetil**, and **corticosteroids**, agents used together as a triple immunosuppressive regimen primarily for the prevention of organ transplant rejection (most commonly kidney and liver transplantation). - **Everolimus** is an mTOR inhibitor, blocking T-cell activation and proliferation by inhibiting the mTOR pathway, thereby reducing immune response and graft rejection risk. - **Mycophenolate mofetil** is a reversible inhibitor of inosine monophosphate dehydrogenase, suppressing the de novo synthesis of guanosine nucleotides, and thereby inhibiting lymphocyte proliferation. - **Corticosteroids** (such as prednisolone or methylprednisolone) act as broad immunosuppressants, reducing inflammation and multiple aspects of immune activation via glucocorticoid receptor-mediated effects. Evidence shows that this combination can provide effective immunosuppression with a safety and efficacy profile similar to regimens using calcineurin inhibitors, with potential benefits for renal function by reducing calcineurin inhibitor exposure[1][3][4].